DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc.
Your view on DMAC
Overview
What the company does, where it operates, and who runs it.
About DiaMedica Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dietrich John Pauls MBA
- Headquarters
- Two Carlson Parkway, Minneapolis, MN, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dietrich John Pauls MBA
- Headquarters
- Two Carlson Parkway, Minneapolis, MN, US
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases.
The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke.
It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for DiaMedica Therapeutics Inc., and the rating behind it. DMAC last traded at $6.47; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for DiaMedica Therapeutics Inc.. Starting points for DiaMedica Therapeutics Inc.: EPS -$0.70, beta 0.97 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for DiaMedica Therapeutics Inc.. DiaMedica Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for DiaMedica Therapeutics Inc.. Trailing twelve-month EPS for DiaMedica Therapeutics Inc. stands at -$0.70. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for DiaMedica Therapeutics Inc.. DiaMedica Therapeutics Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
DiaMedica Therapeutics Inc. valued side by side against its closest peers. DiaMedica Therapeutics Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold DiaMedica Therapeutics Inc., and how their positions are changing. At a $348.6M market value, institutional positions materially move DiaMedica Therapeutics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by DiaMedica Therapeutics Inc. executives and directors. Shares of DiaMedica Therapeutics Inc. have traded between $3.19 and $7.49 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming DiaMedica Therapeutics Inc.. DiaMedica Therapeutics Inc. is a $348.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming DiaMedica Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for DiaMedica Therapeutics Inc.. Coverage tracks DiaMedica Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.